Imatinib in COVID-19: hope and caution.

Bernal-Bello, David; Morales-Ortega, Alejandro; Isabel Farfán-Sedano, Ana; de Tena, Jaime García; Martín-López, Juan Víctor San

Bernal-Bello, David; Morales-Ortega, Alejandro; Isabel Farfán-Sedano, Ana; de Tena, Jaime García; Martín-López, Juan Víctor San.

Bernal-Bello D; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid 28942, Spain. Electronic address: david.bernal@salud.madrid.org.
Morales-Ortega A; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid 28942, Spain; Department of Medicine, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
Isabel Farfán-Sedano A; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid 28942, Spain.
de Tena JG; Department of Medicine, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
Martín-López JVS; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid 28942, Spain.

Lancet Respir Med ; 9(9): 938-939, 2021 09.

Article in English | MEDLINE | ID: covidwho-1275792

Subject(s)

COVID-19; Hope; Humans; Imatinib Mesylate; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google